Zai Lab shares are trading higher after the company obtained Breakthrough Therapy Designation for efgartigimod alfa injection in China.
Portfolio Pulse from Benzinga Newsdesk
Zai Lab has received Breakthrough Therapy Designation for its efgartigimod alfa injection in China, leading to a rise in its share prices.
September 18, 2023 | 2:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Zai Lab's stock price is likely to increase in the short term due to the Breakthrough Therapy Designation for its efgartigimod alfa injection in China.
The Breakthrough Therapy Designation is a significant regulatory milestone that can expedite the development and review of a drug. This positive news is likely to boost investor confidence in Zai Lab, leading to an increase in its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100